Word limits best explain failings of industry supported meta-analyses
- 9 November 2006
- Vol. 333 (7576) , 1021.2-1021
- https://doi.org/10.1136/bmj.39024.372662.1f
Abstract
Footnotes Competing interests: JJD has contributed to the Cochrane Collaboration for over a decade, is currently a member of the steering group of the Cochrane Collaboration and Treasurer. He has co-authored 14 Cochrane reviews, and is the lead editor of the statistical section of the Cochrane Handbook. The views expressed here are his own and not necessarily those of the Cochrane Collaboration. His previous unit (Centre for Statistics in Medicine, Oxford) received funding from Pfizer and Searle to undertake the review mentioned in reference 2 and JJD received consultancy fees from Pfizer from 2001-2. Both his previous and current units have received royalties from the BMJ on sales of reprints of reference 2.Keywords
This publication has 4 references indexed in Scilit:
- Cochrane reviews compared with industry supported meta-analyses and other meta-analyses of the same drugs: systematic reviewBMJ, 2006
- Celecoxib for rheumatoid arthritisPublished by Wiley ,2002
- Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trialsBMJ, 2002
- Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid ArthritisJAMA, 2000